Arbutus Biopharma Corporation
ABUS
$4.45
$0.020.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 529.00K | 10.74M | 1.76M | 1.57M | 1.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 529.00K | 10.74M | 1.76M | 1.57M | 1.34M |
| Cost of Revenue | 5.78M | 5.50M | 8.96M | 8.81M | 14.27M |
| Gross Profit | -5.25M | 5.24M | -7.20M | -7.24M | -12.93M |
| SG&A Expenses | 3.04M | 3.33M | 5.83M | 4.71M | 4.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.82M | 8.83M | 14.79M | 13.52M | 18.81M |
| Operating Income | -8.29M | 1.91M | -13.03M | -11.95M | -17.47M |
| Income Before Tax | -7.74M | 2.52M | -24.53M | -12.53M | -19.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.74M | 2.52M | -24.53M | -12.53M | -19.72M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.74M | 2.52M | -24.53M | -12.53M | -19.72M |
| EBIT | -8.29M | 1.91M | -13.03M | -11.95M | -17.47M |
| EBITDA | -8.28M | 1.92M | -12.70M | -11.62M | -17.14M |
| EPS Basic | -0.04 | 0.01 | -0.13 | -0.07 | -0.10 |
| Normalized Basic EPS | -0.02 | 0.01 | -0.04 | -0.03 | -0.05 |
| EPS Diluted | -0.04 | 0.01 | -0.13 | -0.07 | -0.10 |
| Normalized Diluted EPS | -0.02 | 0.01 | -0.04 | -0.03 | -0.05 |
| Average Basic Shares Outstanding | 191.78M | 191.55M | 190.71M | 189.70M | 189.00M |
| Average Diluted Shares Outstanding | 191.78M | 192.40M | 190.71M | 189.70M | 189.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |